Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
87.89
-0.78 (-0.88%)
At close: Jun 26, 2026, 4:00 PM EDT
88.00
+0.11 (0.13%)
After-hours: Jun 26, 2026, 7:37 PM EDT
Spyre Therapeutics Employees
Spyre Therapeutics had 102 employees as of December 31, 2025. The number of employees increased by 37 or 56.92% compared to the previous year.
Employees
102
Change (1Y)
37
Growth (1Y)
56.92%
Revenue / Employee
n/a
Profits / Employee
-$1,327,705
Market Cap
7.63B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
SYRE News
- 2 days ago - Spyre Therapeutics files automatic mixed securities shelf - TheFly
- 3 days ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends
- 5 days ago - Spyre Therapeutics price target raised to $135 from $115 at Deutsche Bank - TheFly
- 12 days ago - Spyre Therapeutics price target raised to $100 from $80 at Wedbush - TheFly
- 13 days ago - Spyre Therapeutics price target raised to $112 from $98 at BTIG - TheFly
- 13 days ago - Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
- 13 days ago - Spyre Therapeutics announces SKYLINE trial achieves primary endpoint - TheFly
- 13 days ago - Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - GlobeNewsWire